GLUMETZA 1000 MG
METFORMIN HYDROCHLORIDE : 1000 MG · DIN 02300451 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is GLUMETZA?
GLUMETZA 1000 MG contains METFORMIN HYDROCHLORIDE : 1000 MG. It is listed in the Health Canada Drug Product Database under DIN 02300451, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is GLUMETZA used for?
Control of hyperglycemia in adults with type 2 diabetes as an adjunct to diet, exercise, and weight reduction, or when insulin is inappropriate. Monotherapy or with a sulfonylurea.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02300451 |
|---|---|
| Brand name | GLUMETZA |
| Generic / active ingredient | METFORMIN HYDROCHLORIDE : 1000 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 1000 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BA02 METFORMIN |
| AHFS class | 08:12.16.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Dec-2020 |
How is it administered?
Initial: 1000 mg once daily with evening meal. Increase by 500 mg weekly. Max: 2000 mg/day. Take whole with food. Adjust for renal impairment (Max 1000 mg if eGFR 30-45).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 mentioned but content not visible), though standard room temperature is typical for such products.
How is it supplied?
500 mg: bottle of 500 tablets; 1000 mg: bottle of 90 tablets; 1000 mg (SB): bottle of 1000 tablets.
Contraindications
Hypersensitivity; Type 1 diabetes; metabolic acidosis; history of lactic acidosis; severe renal impairment (eGFR <30 mL/min/1.73 m2); excessive alcohol; severe hepatic dysfunction; pregnancy/breastfeeding.
Warnings and precautions
Serious Warning: Lactic acidosis is a rare but fatal complication. Risk increases with renal impairment, age, and alcohol. Monitor Vitamin B12 and TSH levels. Risk of hemolytic anemia.
What can be used instead?
Other Canadian products sharing ATC code A10BA02 METFORMIN. 45 of 122 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-METFORMIN | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494418 |
| AG-METFORMIN | 850 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494442 |
| APO-METFORMIN ER | 1000 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02460653 |
| APO-METFORMIN ER | 500 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02305062 |
| AURO-METFORMIN | 850 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02438283 |
| GLUCOPHAGE | 500 MG | TABLET | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02099233 |
| GLUMETZA | 500 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02268493 |
| JAMP METFORMIN | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380196 |
| JAMP METFORMIN | 850 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380218 |
| M-METFORMIN | 1000 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02548275 |
Who else supplies METFORMIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METFORMIN appears in 1377 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.